PHILADELPHIA, Feb. 2, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the “Company”), announced that the Company, via its manufacturing subcontractor, received a favorable response from the Food and Drug Administration (“FDA”) Seattle District Office (“DO”) related to the latest response to the Prior Approval Inspection submitted on Dec.11, 2009, and noted in Hemispherx’ press release on Dec.16, 2009. The DO has accepted that certain manufacturing issues noted in the pre-approval inspection at the facility have been fully addressed and has made a recommendation for manufacturing approval with the Company’s subcontractor listed as a manufacturing site to the FDA Office of Compliance in Washington, DC.
